Dr. Joseph W LeMaster, MD MPH

Claim this profile
Studies Colorectal Cancer
1 reported clinical trial
2 drugs studied

Clinical Trials Joseph W LeMaster, MD MPH is currently running

Image of trial facility.

Screening Tool Implementation

for Colorectal Cancer

Although implementation intentions (I2)-based tools enhance colorectal cancer (CRC) screening uptake, prior studies have not tested their implementation into routine primary care delivery. In this study, investigators will conduct a cluster-randomized trial in 20 US primary care clinics. Specific aims for the project will be: 1) to test whether a Normalization Process Theory-informed Participatory Learning in Action (NPT-PLA intervention) implementation of a proven implementation Intentions-based colorectal cancer screening tool ("I2") improves screening uptake (i.e. screening order and completion) within 6 months of patient enrollment versus usual quality improvement (control) implementation; and 2) to evaluate the facilitators and barriers of each implementation arm using the 2022 expanded Normalization Process Theory (NPT) framework. Multi-disciplinary clinic 'implementation teams' that include clinic staff and patients whose preferred language is Spanish will meet monthly during the first 6 months of clinic participation and aim to integrate into routine primary care the "I2" CRC screening tool, using the NPT-PLA intervention or control approach. The I2 tool addresses the "when," "where" and "how" details of stool sample or colonoscopy screening. The I2 tool will be delivered via an on-line survey or (if patients prefer) by paper form customized for use in English or Spanish. At least 100 patients in each clinic will be enrolled in the first 6 months of clinic participation (2000 in total). All patients eligible for CRC screening will be offered the I2 tool. Their choices will be communicated automatically to clinics for order entry. Primary (Aim 1) outcomes will be CRC screening orders placed (by clinic staff); completion of the I2 tool and CRC screening completion (by patients) over 6 months of patient follow-up. For Aim 2, surveys based on the NPT domains (the "NOMAD") will be used to assess staff comprehension of their role in implementing the I2-based CRC screening tool, its salience, their buy-in, feasibility of altering workflows, and the potential impact of using the tool in their setting. Investigators will conduct summative qualitative focus group discussions in all participating clinics after 6 months of clinic participation. The study will provide important information on barriers and facilitators of embedding NPT-PLA interventions in "real-world" primary care clinical settings.

Recruiting

1 award

N/A

1 criteria

More about Joseph W LeMaster, MD MPH

Clinical Trial Related

1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial

Treatments Joseph W LeMaster, MD MPH has experience with

  • NPT-PLA
  • Usual Quality Improvement

Breakdown of trials Joseph W LeMaster, MD MPH has run

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Joseph W LeMaster, MD MPH specialize in?

Is Joseph W LeMaster, MD MPH currently recruiting for clinical trials?

Are there any treatments that Joseph W LeMaster, MD MPH has studied deeply?

What is the best way to schedule an appointment with Joseph W LeMaster, MD MPH?

Is there any support for travel costs?